Eli Lilly and Co
LLY: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$238.00 | Tfpt | Pssktqmlkz |
Eli Lilly Earnings: Solid Results and Strong Mounjaro Data Set Up Robust Long-Term Growth Potential
Eli Lilly reported solid first-quarter results slightly below our projections, and we don't expect any major changes to our fair value estimate. In tandem with earnings, Lilly disclosed strong phase 3 Mounjaro data (Surmount 2) reflecting 15.7% average weight loss on the highest dose. The strong data reinforces our peak annual sales estimate for the drug above $18 billion for both weight loss and diabetes.